Lovastatin (Mevilonin, MK-803, 6-alpha-Methylcompactin, BRN 3631989)

Statin compound. Potent competitive HMG-CoA reductase inhibitor. Anti-hypercholesterolemic agent. Cholesterol/isoprenoid biosynthesis inhibitor. Blocks the production of mevalonate, a critical compound in the production of cholesterol and isoprenoids. Inhibits the isoprenylation of Ras and Rho family GTPases. Causes cell cycle arrest in G1 and G2/M phases through modulation of proteasome in cancer cell lines. Smooth muscle cell proliferation inhibitor. Apoptosis inducer. Anticancer compound. Anti-adhesive, immunomodulatory and anti-inflammatory compound. Stimulates bone formation. Increases cellular resistance to anticancer agents such as doxorubicin and etoposide. Suppresses ICAM-1-LFA-1 interactions, which blocks virus replication and infection. Anti-hypertensive agent. Suppresses TNF-induced NF-kappaB activation. Modulates key cell signaling pathways, like Ras, MAPK and EGFR (modest).\n\nStorage and Stability:\nShort-term Storage: +4 degrees C\nLong-term Storage: -20 degrees C\nStable for at least 2 years after receipt when stored at -20 degrees C.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

045022

Size

5mg

Purity

>98% (HPLC)

References

Product Reference: \n?Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent: A.W. Alberts, et al.; PNAS 77, 3957 (1980)\n?All ras proteins are polyisoprenylated but only some are palmitoylated: J.F. Hancock, et al.; Cell 57, 1167 (1989)\n?Cell cycle-specific effects of lovastatin: M. Jakobisiak, et al.; PNAS 88, 3628 (1991)\n?Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types: P. Negre-Aminou, et al.; Biochim. Biophys. Acta 1345, 259 (1997)\n?Lovastatin-induced inhibition of HL-60 cell proliferation via cell cycle arrest and apoptosis: W.H. Park, et al.; Anticancer Res. 19, 3133 (1999)\n?Statins as a newly recognized type of immunomodulator: B. Kwak, et al.; Nat. Med. 6, 1399 (2000)\n?Lovastatin and simvastatin are modulators of the proteasome: C. Wojcik, et al.; Int. J. Biochem. Cell Biol. 32, 957 (2000)\n?Statins and bone formation: I.R. Garrett, et al.; Curr. Pharm. Des. 7, 715 (2001)\n?The HMG-CoA reductase inhibitor lovastatin protects cells from the antineoplastic drugs doxorubicin and etoposide: R.V. Bardeleben, et al.; Int. J. Mol. Med. 10, 473 (2002)\n?HMG-CoA reductase inhibitors as immunomodulators: potential use in transplant rejection: L.J. Raggatt & N.C. Partridge; Drugs 62, 2185 (2002) (Review)\n?HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis: W.W. Wong, et al.; Leukemia 16, 508 (2002)\n?The statins as anticancer agents: K.K. Chan, et al.; Clin. Cancer Res. 9,10 (2003)\n?Anti-inflammatory and immunomodulatory effects of statins: L.M. Blanco-Colio, et al.; Kidney Int. 63, 12 (2003)\n?Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1: J.F. Giguere & M.J. Tremblay; J. Virol. 78, 12062 (2004)\n?HMG CoA reductase inhibitors (statins) to treat Epstein-Barr virus-driven lymphoma: J.I. Cohen; Br. J. Cancer 92, 1593 (2005)\n?Beyond lipid lowering: the anti-hypertensive role of statins: V. Chopra, et al.; Cardiovasc. Drugs Ther. 21, 161 (2007)\n?Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-kappaB pathway: K.S. Ahn, et al.; Biochem. Pharmacol. 75, 907 (2008)\n?Therapeutic Levels Of The Hydroxmethylglutaryl-Coenzyme A Reductase Inhibitor Lovastatin Activate Ras Signaling Via Phospholipase D2: K.J. Cho, et al.; Mol. Cell. Biol. 31, 1110 (2011)\n?

Alternative Names

Mevilonin, MK-803, 6-alpha-Methylcompactin, BRN 3631989